19218

543998

VALIANTLAB

img img img img
No Data Available

VALIANT LABORATORIES LTD Share Price Update

As of the latest trading session, VALIANT LABORATORIES LTD share price is currently at ₹57.28, which is down by ₹-1.82 from its previous closing. Today, the stock has fluctuated between ₹56.00 and ₹60.65. Over the past year, VALIANT LABORATORIES LTD has achieved a return of -27.37%. In the last month alone, the return has been -0.11%.

VALIANT LABORATORIES LTD performance

Today’s low

Today’s high

₹ 56.00 ₹ 60.65
₹ 57.28

52 week low

52 week high

₹ 56.00 ₹ 115.54
₹ 57.28

Open Price

₹ 60.00

Prev. Close

₹ 59.10

Volume (Shares)

25314.00

Total traded value

₹ 14.49

Upper Circuit

₹ 70.92

Lower Circuit

₹ 47.28

info

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

VALIANT LABORATORIES LTD fundamentals


  • Market cap (Cr)

    311.10

  • P/E Ratio (TTM)

    61.85

  • Beta

    0.87

  • Book Value / share

    58.43

  • Return on equity

    -1.40%

  • EPS (TTM)

    0.97

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.03

info icon alternate text
  • Market cap (Cr)

    309.40

  • P/E Ratio (TTM)

    61.85

  • Beta

    0.80

  • Book Value / share

    58.43

  • Return on equity

    -1.40%

  • EPS (TTM)

    0.97

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.03

info icon alternate text

VALIANT LABORATORIES LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2025 (Values in Cr)
Revenue 54.74
Operating Expense 55.24
Net Profit 0.03
Net Profit Margin (%) 0.05
Earnings Per Share (EPS) 0.01
EBITDA 0.86
Effective Tax Rate (%) 72.72
Particulars SEP 2025 (Values in Cr)
Revenue 45.99
Operating Expense 46.58
Net Profit 0.17
Net Profit Margin (%) 0.36
Earnings Per Share (EPS) 0.03
EBITDA 0.91
Effective Tax Rate (%) 34.61
Particulars JUN 2025 (Values in Cr)
Revenue 51.01
Operating Expense 49.23
Net Profit 1.82
Net Profit Margin (%) 3.56
Earnings Per Share (EPS) 0.42
EBITDA 3.03
Effective Tax Rate (%) 25.71
Particulars MAR 2025 (Values in Cr)
Revenue 57.77
Operating Expense 54.50
Net Profit 3.24
Net Profit Margin (%) 5.60
Earnings Per Share (EPS) 0.74
EBITDA 4.47
Effective Tax Rate (%) 17.60
Particulars DEC 2024 (Values in Cr)
Revenue 35.23
Operating Expense 35.17
Net Profit 1.60
Net Profit Margin (%) 4.54
Earnings Per Share (EPS) 0.37
EBITDA 1.29
Effective Tax Rate (%) -122.22
Particulars MAR 2025 (Values in Cr)
Revenue 133.36
Operating Expense 140.24
Net Profit -2.15
Net Profit Margin (%) -1.61
Earnings Per Share (EPS) -0.50
EBITDA 0.75
Effective Tax Rate (%) -48.27
Particulars MAR 2024 (Values in Cr)
Revenue 182.05
Operating Expense 192.49
Net Profit 0.34
Net Profit Margin (%) 0.18
Earnings Per Share (EPS) 0.14
EBITDA 1.27
Effective Tax Rate (%) 145.33
Particulars MAR 2023 (Values in Cr)
Revenue 333.91
Operating Expense 300.63
Net Profit 29.00
Net Profit Margin (%) 8.68
Earnings Per Share (EPS) 8.91
EBITDA 39.95
Effective Tax Rate (%) 23.96
Particulars MAR 2022 (Values in Cr)
Revenue 291.52
Operating Expense 251.76
Net Profit 27.50
Net Profit Margin (%) 9.43
Earnings Per Share (EPS) 16.99
EBITDA 44.26
Effective Tax Rate (%) 34.07
Particulars MAR 2025 (Values in Cr)
Book Value / Share 53.93
ROE % -1.43
ROCE % -0.95
Total Debt to Total Equity 0.42
EBITDA Margin -0.82
Particulars MAR 2024 (Values in Cr)
Book Value / Share 54.51
ROE % -1.71
ROCE % -1.63
Total Debt to Total Equity 0.41
EBITDA Margin -1.05
Particulars MAR 2023 (Values in Cr)
Book Value / Share 30.86
ROE % 28.86
ROCE % 23.73
Total Debt to Total Equity 0.60
EBITDA Margin 11.96
Particulars MAR 2025 (Values in Cr)
Book Value / Share 53.94
ROE % -1.40
ROCE % -1.05
Total Debt to Total Equity 0.25
EBITDA Margin -0.82
Particulars MAR 2024 (Values in Cr)
Book Value / Share 54.52
ROE % -1.70
ROCE % -1.68
Total Debt to Total Equity 0.36
EBITDA Margin -1.05
Particulars MAR 2023 (Values in Cr)
Book Value / Share 30.86
ROE % 33.73
ROCE % 26.00
Total Debt to Total Equity 0.71
EBITDA Margin 11.96
Particulars MAR 2022 (Values in Cr)
Book Value / Share 43.89
ROE % 34.37
ROCE % 37.35
Total Debt to Total Equity 0.39
EBITDA Margin 15.18
Particulars MAR 2021 (Values in Cr)
Book Value / Share 84.36
ROE % 34.53
ROCE % 54.13
Total Debt to Total Equity 0.01
EBITDA Margin 28.19
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 75.99
Total Assets 400.85
Total Liabilities 400.85
Total Equity 234.31
Share Outstanding 4
Price to Book Ratio 1.42
Return on Assets (%) -0.54
Return on Capital (%) -0.62
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 106.21
Total Assets 342.68
Total Liabilities 342.68
Total Equity 236.86
Share Outstanding 4
Price to Book Ratio 2.67
Return on Assets (%) 0.09
Return on Capital (%) 0.1
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.34
Total Assets 212.96
Total Liabilities 212.96
Total Equity 100.49
Share Outstanding 3
Price to Book Ratio 0.00
Return on Assets (%) 13.61
Return on Capital (%) 18.14
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 27.33
Total Assets 317.28
Total Liabilities 317.28
Total Equity 234.38
Share Outstanding 4
Price to Book Ratio 1.42
Return on Assets (%) -0.67
Return on Capital (%) -0.73
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 96.72
Total Assets 324.72
Total Liabilities 324.72
Total Equity 236.88
Share Outstanding 4
Price to Book Ratio 2.67
Return on Assets (%) 0.10
Return on Capital (%) 0.11
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.45
Total Assets 212.75
Total Liabilities 212.75
Total Equity 100.49
Share Outstanding 3
Price to Book Ratio 0.00
Return on Assets (%) 13.62
Return on Capital (%) 18.14
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 20.13
Total Assets 181.81
Total Liabilities 181.81
Total Equity 71.46
Share Outstanding 1
Price to Book Ratio 0.00
Return on Assets (%) 15.12
Return on Capital (%) 20.81
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 18.93
Total Assets 106.31
Total Liabilities 106.31
Total Equity 88.58
Share Outstanding 1
Price to Book Ratio 0.00
Return on Assets (%) 28.77
Return on Capital (%) 34.4
Particulars MAR 2025 (Values in Cr)
Net Income -1.51
Cash from Operations -1.15
Cash from Investing -52.76
Cash from Financing 44.65
Net change in Cash -6.80
Free Cash Flow 112.70
Particulars MAR 2024 (Values in Cr)
Net Income -0.76
Cash from Operations 0.90
Cash from Investing -143.87
Cash from Financing 152.44
Net change in Cash 10.45
Free Cash Flow 46.77
Particulars MAR 2023 (Values in Cr)
Net Income 38.13
Cash from Operations 64.85
Cash from Investing -55.16
Cash from Financing -0.93
Net change in Cash -0.05
Free Cash Flow 102.53
Particulars MAR 2025 (Values in Cr)
Net Income -1.44
Cash from Operations -25.08
Cash from Investing 24.97
Cash from Financing -0.50
Net change in Cash 2.57
Free Cash Flow -24.52
Particulars MAR 2024 (Values in Cr)
Net Income -0.75
Cash from Operations 47.80
Cash from Investing -182.72
Cash from Financing 135.79
Net change in Cash 1.85
Free Cash Flow 51.55
Particulars MAR 2023 (Values in Cr)
Net Income 38.13
Cash from Operations 31.75
Cash from Investing -21.17
Cash from Financing -1.53
Net change in Cash 0.24
Free Cash Flow 38.82
Particulars MAR 2022 (Values in Cr)
Net Income 41.70
Cash from Operations 16.71
Cash from Investing -12.23
Cash from Financing 6.18
Net change in Cash -3.80
Free Cash Flow 23.59
Particulars MAR 2021 (Values in Cr)
Net Income 47.02
Cash from Operations 25.56
Cash from Investing -16.66
Cash from Financing 11.42
Net change in Cash 3.86
Free Cash Flow 27.23
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 26.32 11.39 1.36 201.70 23.12 / 42.05
BLISS GVS PHARMA LTD 217.50 20.79 2.03 2300.91 105.05 / 244.05
CIPLA LTD 1357.80 23.07 3.33 109680.46 1283.00 / 1672.20
FERMENTA BIOTECH LIMITED 332.45 11.06 2.50 978.43 219.00 / 399.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 26.32 25.31 3.66 201.70 23.12 / 42.05
AMRUTAJAN HEALTH LTD 606.35 30.32 5.12 1753.00 548.05 / 789.95
ASTRAZENECA PHARMA IND LT 8850.60 106.36 27.69 22126.50 6501.60 / 10653.05
BLISS GVS PHARMA LTD 217.50 29.63 2.08 2300.91 105.05 / 244.05

VALIANT LABORATORIES LTD shareholding pattern

Holding

25.05%
74.93%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

VALIANT LABORATORIES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
57.28 -3.07 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 59.20
  • 26 Days 61.00
  • 10 Days 59.60
  • 50 Days 63.70
  • 12 Days 59.80
  • 100 Days 69.60
  • 20 Days 60.40
  • 200 Days 78.70
59.04 PIVOT

First Support

58.07

First Resistance

60.06

Second Support

57.05

Second Resistance

61.03

Third Support

56.08

Third Resistance

62.05

RSI

43.15

ADX

14.03

MACD

-1.19

Williams % R

-84.00

Commodity Channel Index (CCI)

-51.18

Date

2026-02-26

Week

21940.00

Same Day

3835.00

Month

52239.00

1 Year

0.87

3 Year

1.08

Over 1 Month

-0.11%

down

Over 1 Year

-27.37%

down

Over 3 Months

-15.67%

down

Over 3 Years

-27.96%

down

Over 6 Months

-31.56%

down

Over 5 Years

0.00%

down

VALIANT LABORATORIES LTD Corporate Actions

Top Gainers

VALIANT LABORATORIES LTD Share Price

Valiant Laboratories Limited was originally formed as a Partnership Firm as M/s. Bharat Chemicals' through deed of partnership dated October 17, 1980. The said Partnership Firm, M/s. Bharat Chemicals thereafter converted into a Public Company to 'Valiant Laboratories Limited' via Certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies.

The Company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. The Company gradually, commenced manufacturing of Paracetamol by late 1982. Paracetamol (Scientific name: Acetaminophen or para-hydroxyacetanilide - C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. It manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of customers.

Paracetamol is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. Paracetamol is often found combined with other drugs in many over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products.

Presently, the Company is engaged in manufacturing and dealing in Pharmaceuticals and specility chemicals. The manufacturing facility is located at Tarapur Industrial Area, Boisar in the State of Maharashtra, with an annual installed capacity of 9,000 MTPA. Within the Manufacturing Facility located at Tarapur Industrial Area, Palghar, Maharashtra, the Company has an in-house R&D infrastructure which is equipped with analytical laboratory and infrastructure for developmental activities in existing product. The Company is promoted by Shantilal Shivji Vora, Director and Dhanvallabh Ventures LLP (DVL).

In July, 2022 the Company formed its wholly owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL) to diversify the business activities.

The Company launched a public issue comprising a fresh issue of 10,890,000 equity shares of Rs 10 each by raising funds of Rs 15.24 crore on October 03, 2023.

Company enhanced the manufacturing capacity of the Tarapur plant from 750 MT to 900 MT per month in FY25.

Parent organization Indian Private
NSE symbol VALIANTLAB
Founded 2021
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Valiant Laboratories Ltd?

Answer Field

Valiant Laboratories Ltd share price is for NSE ₹ 57.28 & for BSE ₹ 56.96 as on Feb 27 2026 03:30 PM.

What is the Market Cap of Valiant Laboratories Ltd Share?

Answer Field

The market cap of Valiant Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Feb 27 2026 03:30 PM.

What is the 52 Week High and Low of Valiant Laboratories Ltd?

Answer Field

The 52 Week High and Low of Valiant Laboratories Ltd for NSE is ₹ 115.54 and ₹ 56.00 and for BSE is ₹ 114.72 and ₹ 55.85.

What is 1 year return for Valiant Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -27.37%.

What is the P/E Ratio of Valiant Laboratories Ltd Share?

Answer Field

As on Feb 27 2026 03:30 PM the price-to-earnings (PE) ratio for Valiant Laboratories Ltd share is 61.85.

What is the PB ratio of Valiant Laboratories Ltd Share?

Answer Field

As on Feb 27 2026 03:30 PM, the price-to-book (PB) ratio for Valiant Laboratories Ltd share is 58.43.

How to Buy Valiant Laboratories Ltd Share?

Answer Field

You can trade in Valiant Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Valiant Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Valiant Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Valiant Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59